[go: up one dir, main page]

FR2984359B1 - METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER - Google Patents

METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER

Info

Publication number
FR2984359B1
FR2984359B1 FR1162027A FR1162027A FR2984359B1 FR 2984359 B1 FR2984359 B1 FR 2984359B1 FR 1162027 A FR1162027 A FR 1162027A FR 1162027 A FR1162027 A FR 1162027A FR 2984359 B1 FR2984359 B1 FR 2984359B1
Authority
FR
France
Prior art keywords
prognosis
vitro
diagnosis
prostate cancer
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1162027A
Other languages
French (fr)
Other versions
FR2984359A1 (en
Inventor
Philippe Perot
Francois Mallet
Nathalie Mugnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Hospices Civils de Lyon HCL
Original Assignee
Biomerieux SA
Hospices Civils de Lyon HCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA, Hospices Civils de Lyon HCL filed Critical Biomerieux SA
Priority to FR1162027A priority Critical patent/FR2984359B1/en
Priority to US14/367,635 priority patent/US11459605B2/en
Priority to PCT/FR2012/052970 priority patent/WO2013093324A2/en
Priority to ES12819084.0T priority patent/ES2659556T3/en
Priority to EP12819084.0A priority patent/EP2794923B8/en
Priority to CN201280063390.6A priority patent/CN104024434B/en
Publication of FR2984359A1 publication Critical patent/FR2984359A1/en
Application granted granted Critical
Publication of FR2984359B1 publication Critical patent/FR2984359B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR1162027A 2011-12-20 2011-12-20 METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER Expired - Fee Related FR2984359B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1162027A FR2984359B1 (en) 2011-12-20 2011-12-20 METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER
US14/367,635 US11459605B2 (en) 2011-12-20 2012-12-18 Method for the diagnosis or prognosis, in vitro, of prostate cancer
PCT/FR2012/052970 WO2013093324A2 (en) 2011-12-20 2012-12-18 Method for the diagnosis or prognosis, in vitro, of prostate cancer
ES12819084.0T ES2659556T3 (en) 2011-12-20 2012-12-18 Procedure for the diagnosis, in vitro, of prostate cancer
EP12819084.0A EP2794923B8 (en) 2011-12-20 2012-12-18 Method for the diagnosis in vitro of prostate
CN201280063390.6A CN104024434B (en) 2011-12-20 2012-12-18 In-vitro diagnosis or the method for prognosis for carcinoma of prostate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1162027A FR2984359B1 (en) 2011-12-20 2011-12-20 METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER

Publications (2)

Publication Number Publication Date
FR2984359A1 FR2984359A1 (en) 2013-06-21
FR2984359B1 true FR2984359B1 (en) 2017-11-24

Family

ID=47628302

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1162027A Expired - Fee Related FR2984359B1 (en) 2011-12-20 2011-12-20 METHOD FOR THE DIAGNOSIS OR PROGNOSIS, IN VITRO, OF PROSTATE CANCER

Country Status (6)

Country Link
US (1) US11459605B2 (en)
EP (1) EP2794923B8 (en)
CN (1) CN104024434B (en)
ES (1) ES2659556T3 (en)
FR (1) FR2984359B1 (en)
WO (1) WO2013093324A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2984362B1 (en) * 2011-12-20 2017-11-24 Biomerieux Sa METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF LUNG CANCER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US87436A (en) * 1869-03-02 Improvement in prttning-shbars
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
EP1415005B1 (en) * 2000-12-07 2012-11-21 Novartis Vaccines and Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU2002351332A1 (en) * 2001-12-07 2003-06-23 Chiron Corporation Endogenous retrovirus polypeptides linked to oncogenic transformation
FR2984362B1 (en) * 2011-12-20 2017-11-24 Biomerieux Sa METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF LUNG CANCER

Also Published As

Publication number Publication date
US11459605B2 (en) 2022-10-04
WO2013093324A3 (en) 2013-12-19
FR2984359A1 (en) 2013-06-21
WO2013093324A2 (en) 2013-06-27
US20140370503A1 (en) 2014-12-18
ES2659556T3 (en) 2018-03-16
EP2794923B1 (en) 2017-09-20
EP2794923A2 (en) 2014-10-29
CN104024434A (en) 2014-09-03
EP2794923B8 (en) 2018-03-21
CN104024434B (en) 2016-11-16

Similar Documents

Publication Publication Date Title
EP2831281A4 (en) MOLECULAR MARKERS FOR THE PREDICTION OF PROSTATE CANCER PROGNOSIS, METHOD AND KIT THEREOF
FR2944019B1 (en) METHOD FOR DETERMINING PRODEFENSIN-A6 FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
EP2825669A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA
EP2776830A4 (en) METHOD OF PREDICTING THE PROGNOSIS OF BREAST CANCER
EP2687796A4 (en) REFRIGERATOR, AND APPARATUS AND METHOD FOR REFRIGERATOR DIAGNOSIS
EP4036119C0 (en) ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL FOR CANCER DIAGNOSIS
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
EP2828405A4 (en) PANEL OF MARKERS FOR THE DETECTION OF CANCER
GB2513275B (en) Biomarkers for Breast Cancer Prediction and Diagnosis
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
ZA201300519B (en) Novel antibody for the diagnosis and/or prognosis of cancer
EP2698634A4 (en) BIOMARKER FOR BREAST CANCER
EP2524702A4 (en) DIAGNOSIS FOR CANCER
ZA201401326B (en) Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer
EP2988131A4 (en) Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
EP2825886A4 (en) MEANS AND METHODS FOR THE DIAGNOSIS AND THERAPEUTICS OF DISEASES
EP2785871A4 (en) CTC BIOMARKER ASSAY FOR COMBAT BREAST CANCER BRAIN METASTASIS
EP2515114A4 (en) METHOD FOR THE DIAGNOSIS OF MALIGNANT TUMOR
EP2773774A4 (en) BIOMARKERS FOR THE TREATMENT OF TSLP
SG11201402115TA (en) Methods for diagnosis and/or prognosis of gynecological cancer
PL2444811T3 (en) Methods for the diagnosis or prognosis of colorectal cancer
EP2880443A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF BREAST CANCER
LT2672994T (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
FR2969616B1 (en) PROCESS FOR THE PREPARATION OF CARBENIC PLATINUM COMPLEXES
FR2961810B1 (en) METRONIDAZOLE ESTERS FOR TREATING ROSACEA

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

ST Notification of lapse

Effective date: 20230808